Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New ...
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
在传统的HIV预防方法中,使用抗病毒药物通常需要每日服用,这不仅增加了患者的用药负担,也降低了患者每日坚持服药的依从性。以lenacapavir为代表的长效疗法,将可能为用户提供更为便利的选择。这种疗法通过每年肌肉注射的方式来维持HIV的抑制效果。一 ...
Lenacapavir是一种“first-in-class”长效HIV病毒衣壳抑制剂,可以干扰HIV病毒衣壳蛋白的组装和拆卸,在病毒生命周期的多个阶段发挥作用。它已经获得美国FDA授予的突破性疗法认定,用于HIV病毒感染暴露前预防。2024年,《科学 ...
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...